TripleMed

About:

TripleMed aims to develop innovative and cost-effective solutions for the treatment of aortic aneurysms.

Top Investors: Chemelot Ventures, Limburg Business Development Fund (LBDF)

Description:

TripleMed is developing minimally invasive products against aneurysms, without the need for incisions. The first product fills the aneurysm and prevents blood from entering, whilst leaving a channel for the blood to flow through to reach the other arteries. This enables a better and longer-lasting solution to the problem of aortic aneurysms.

Total Funding Amount:

2M EUR

Headquarters Location:

Maastricht, Limburg, The Netherlands

Founded Date:

2011-01-01

Contact Email:

nfo(AT)triplemedical.com

Founders:

Hans Brom, Michael Jacobs

Number of Employees:

1-10

Last Funding Date:

2017-09-18

IPO Status:

Private

Industries: